hkr.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Estimating the value of novel interventions for Parkinson's disease: an early decision-making model with application to dopamine cell replacement
The Swedish Institute for Health Economics, Lund.
The Swedish Institute for Health Economics, Lund.
Section of Restorative Neurology, Wallenberg Neuroscience Center, University Hospital, Lund.
Section of Restorative Neurology, Wallenberg Neuroscience Center, University Hospital, Lund.
Show others and affiliations
2006 (English)In: Parkinsonism & Related Disorders, ISSN 1353-8020, E-ISSN 1873-5126, Vol. 12, no 7, 443-452 p.Article in journal (Refereed) Published
Abstract [en]

A long-term cost-effectiveness model for early decision-making and estimation of outcomes of novel therapeutic procedures for Parkinson's disease (PD) was developed based on the Hoehn and Yahr (HY) stages of PD. Results provided support for model validity. Model application to a future dopamine cell replacement therapy indicated long-term cost offsets and gains in quality-adjusted life years (QALYs) in early onset PD (HY III-IV), as compared to standard drug therapy. The maximum price premium (i.e., profit or compensation for developmental costs) for the intervention to remain cost-effective was estimated to euro12000-64000 according to cost-per-QALY thresholds of euro38000-70000 and depending on whether all or only medical direct costs are considered. The study illustrates the value of early health economic modeling and the described model shows promise as a means to estimate outcomes and aid decision-making regarding novel interventions for PD.

Place, publisher, year, edition, pages
2006. Vol. 12, no 7, 443-452 p.
Keyword [en]
Parkinson’s disease, Cost-effectiveness, Outcomes, Modeling, Cell therapy
National Category
Neurology
Identifiers
URN: urn:nbn:se:hkr:diva-12320DOI: 10.1016/j.parkreldis.2006.04.006ISI: 000241605700007PubMedID: 16798054OAI: oai:DiVA.org:hkr-12320DiVA: diva2:732156
Available from: 2014-07-03 Created: 2014-07-03 Last updated: 2014-09-15Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Hagell, Peter
In the same journal
Parkinsonism & Related Disorders
Neurology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 26 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf